A research paper discusses the hypothesis that ACE2-stimulating drugs, including ACE inhibitors used for hypertension and diabetes, may increase the risk of severe COVID-19. The author is Taqua R. Khashkhusha from the University of Liverpool. The paper is published under an Open Access license on the Papers with Code platform.
Use Cases
- Reviewing the hypothesis linking ACE inhibitor use to COVID-19 risk based on the described mechanism of ACE2 receptor upregulation.
- Analyzing potential drug interactions for COVID-19 patients with hypertension or diabetes based on the described treatment regimes.
- Studying the role of the ACE2 receptor in coronavirus infection as described for SARS-CoV and SARS-CoV-2.
Strengths
- Authored by a researcher from a recognized institution, the University of Liverpool.
- Published under an Open Access license, facilitating reuse and distribution.
Limitations
- Description metadata is limited; actual data quality requires manual inspection after download.
- Column-level documentation is absent; field semantics must be inferred after download.
- Row count is unknown, which may limit suitability assessment.
Provenance
- Source
- Papers with Code platform, authored by Taqua R. Khashkhusha.